Prophylaxis and Treatment of Acute Graft-Versus-Host Disease

Vogelsang, 2003, Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant, Annu Rev Med, 54, 29, 10.1146/annurev.med.54.101601.152339

Socie, 1999, Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry, N Engl J Med, 341, 14, 10.1056/NEJM199907013410103

Antin, 1992, Cytokine dysregulation and acute graft-versus-host disease, Blood, 80, 2964, 10.1182/blood.V80.12.2964.2964

van Bekkum, 1974, Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora, J Natl Cancer Inst, 52, 401, 10.1093/jnci/52.2.401

Storb, 1983, Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment, N Engl J Med, 308, 302, 10.1056/NEJM198302103080602

Ferrara, 1999, Pathophysiologic mechanisms of acute graft-vs.-host disease, Biol Blood Marrow Transplant, 5, 347, 10.1016/S1083-8791(99)70011-X

Clift, 1990, Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission, Blood, 76, 1867, 10.1182/blood.V76.9.1867.1867

Hill, 1999, Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia, J Clin Invest, 104, 459, 10.1172/JCI6896

Johnson, 1995, Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease, Blood, 85, 3302, 10.1182/blood.V85.11.3302.bloodjournal85113302

Barrett, 1998, T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect, Bone Marrow Transplant, 21, 543, 10.1038/sj.bmt.1701131

Holler, 1990, Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation, Blood, 75, 1011, 10.1182/blood.V75.4.1011.1011

Shalaby, 1989, Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha, Transplantation, 47, 1057, 10.1097/00007890-198906000-00028

Piguet, 1987, Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease, J Exp Med, 166, 1280, 10.1084/jem.166.5.1280

Panoskaltsis-Mortari, 1998, Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice, Blood, 92, 3960, 10.1182/blood.V92.10.3960

Krijanovski, 1999, Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease, Blood, 94, 825, 10.1182/blood.V94.2.825

Bacigalupo, 2001, Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors, Blood, 98, 2942, 10.1182/blood.V98.10.2942

Remberger, 2002, Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors, Bone Marrow Transplant, 29, 391, 10.1038/sj.bmt.1703374

Basara, 2005, Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia, Bone Marrow Transplant, 35, 1011, 10.1038/sj.bmt.1704957

den Haan, 1995, Identification of a graft versus host disease-associated human minor histocompatibility antigen, Science, 268, 1476, 10.1126/science.7539551

Goulmy, 1996, Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation, N Engl J Med, 334, 281, 10.1056/NEJM199602013340501

Sette, 1995, Interaction of antigenic peptides with MHC and TCR molecules, Clin Immunol Immunopathol, 76, S168, 10.1016/S0090-1229(95)90108-6

Yang, 1996, CD40 ligand-dependent T cell activation, Science, 273, 1862, 10.1126/science.273.5283.1862

Freeman, 1993, Cloning of B7-2, Science, 262, 909, 10.1126/science.7694363

Guinan, 1999, Transplantation of anergic histoincompatible bone marrow allografts, N Engl J Med, 340, 1704, 10.1056/NEJM199906033402202

Vezina, 1975, Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle, J Antibiot (Tokyo), 28, 721, 10.7164/antibiotics.28.721

Morice, 1993, Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes, J Biol Chem, 268, 3734, 10.1016/S0021-9258(18)53755-8

Nourse, 1994, Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin, Nature, 372, 570, 10.1038/372570a0

Altmeyer, 1993, Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma, Cytokine, 5, 133, 10.1016/1043-4666(93)90052-7

Storb, 1970, Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts, Transplantation, 9, 240, 10.1097/00007890-197003000-00007

Storb, 1986, Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia, N Engl J Med, 314, 729, 10.1056/NEJM198603203141201

Ringden, 1992, Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings, Bone Marrow Transplant, 9, 19

Storb, 1997, Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation, Blood, 89, 3048, 10.1182/blood.V89.8.3048

Ferrara, 1991, Graft-versus-host disease, N Engl J Med, 324, 667, 10.1056/NEJM199103073241005

Henkart, 1994, Cytotoxic lymphocytes. Two ways to kill target cells, Curr Biol, 4, 923, 10.1016/S0960-9822(00)00207-4

Mason, 1981, Subsets of T cells in the rat mediating lethal graft versus-host disease, Transplantation, 32, 222, 10.1097/00007890-198109000-00008

Fong, 1990, Alloreactive murine CD8+ T cell clones secrete the Th1 pattern of cytokines, J Immunol, 144, 1744, 10.4049/jimmunol.144.5.1744

Groux, 1996, Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells, J Exp Med, 184, 19, 10.1084/jem.184.1.19

Bensinger, 2001, Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers, N Engl J Med, 344, 175, 10.1056/NEJM200101183440303

Mielcarek, 1998, Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products, Blood, 92, 215, 10.1182/blood.V92.1.215.413k10_215_222

Powles, 2000, Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases, Lancet, 355, 1231, 10.1016/S0140-6736(00)02090-0

Yang, 1998, Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12, J Clin Invest, 102, 2126, 10.1172/JCI4992

Shevach, 2001, Control of T-cell activation by CD4+ CD25+ suppressor T cells, Immunol Rev, 182, 58, 10.1034/j.1600-065X.2001.1820104.x

Taylor, 2002, The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality, Blood, 99, 3493, 10.1182/blood.V99.10.3493

Edinger, 2003, CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation, Nat Med, 9, 1144, 10.1038/nm915

Ghiringhelli, 2004, CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative, Eur J Immunol, 34, 336, 10.1002/eji.200324181

Korngold, 1978, Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow, J Exp Med, 148, 1687, 10.1084/jem.148.6.1687

Ho, 2001, The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation, Blood, 98, 3192, 10.1182/blood.V98.12.3192

Michalek, 2003, Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences, Proc Natl Acad Sci U S A, 100, 1180, 10.1073/pnas.0337543100

Gribben, 1996, Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy, Blood, 87, 4887, 10.1182/blood.V87.11.4887.bloodjournal87114887

Blazar, 1998, CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses, J Clin Invest, 102, 473, 10.1172/JCI3741

Zeller, 1999, Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL- 10 and TGF-beta, J Immunol, 163, 3684, 10.4049/jimmunol.163.7.3684

Cavazzana-Calvo, 1990, Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin, Transplantation, 50, 1, 10.1097/00007890-199007000-00001

Andre-Schmutz, 2002, Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation, Lancet, 360, 130, 10.1016/S0140-6736(02)09413-8

Solomon, 2004, Selective depletion of alloreacting CD25+ cells from stem cell allografts can reduce acute graft-versus-host disease following matched related donor transplantation, Blood, 104, 125A, 10.1182/blood.V104.11.426.426

Chen, 2004, Transfer of aflogeneic CD62L(-) memory T cells without graft-versus-host disease, Blood, 103, 1534, 10.1182/blood-2003-08-2987

Anderson, 2003, Memory CD4+ T cells do not induce graft-versus-host disease, J Clin Invest, 112, 101, 10.1172/JCI17601

Xystrakis, 2004, Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset, Eur J Immunol, 34, 408, 10.1002/eji.200324528

Bonini, 1997, HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia, Science, 276, 1719, 10.1126/science.276.5319.1719

Fontaine, 2001, Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease, Nat Med, 7, 789, 10.1038/89907

Ruggeri, 2001, Cellular therapy, Curr Opin Hematol, 8, 355, 10.1097/00062752-200111000-00007

Ruggeri, 2002, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, 295, 2097, 10.1126/science.1068440

Bendelac, 1995, CD1 recognition by mouse NK1+ T lymphocytes, Science, 268, 863, 10.1126/science.7538697

Porcelli, 1995, The CD1 family, Adv Immunol, 59, 1, 10.1016/S0065-2776(08)60629-X

Zeng, 1999, Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease, J Exp Med, 189, 1073, 10.1084/jem.189.7.1073

Furlong, 2000, Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities, Bone Marrow Transplant, 26, 985, 10.1038/sj.bmt.1702639

Thomas, 1975, Bone-marrow transplantation (first of two parts), N Engl J Med, 292, 832, 10.1056/NEJM197504172921605

Ruutu, 1998, How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party, Bone Marrow Transplant, 22, 614, 10.1038/sj.bmt.1701377

Van Lint, 1998, Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone, Blood, 92, 2288

Martin, 1990, A retrospective analysis of therapy for acute graft-versus-host disease, Blood, 76, 1464, 10.1182/blood.V76.8.1464.1464

Weisdorf, 1990, Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation, Blood, 75, 1024, 10.1182/blood.V75.4.1024.1024

Hings, 1993, Prednisone therapy for acute graft-versus-host disease, Transplantation, 56, 577, 10.1097/00007890-199309000-00016

Cahn, 1995, Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study, Transplantation, 60, 939, 10.1097/00007890-199511150-00010

Bacigalupo, 2001, Pre-emptive therapy of acute graft-versus-host disease, Bone Marrow Transplant, 28, 1093, 10.1038/sj.bmt.1703306

Hattori, 1998, Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies, Blood, 91, 4051, 10.1182/blood.V91.11.4051

Stuber, 1999, Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor alpha and not by the FasL-Fas interaction, Gut, 45, 229, 10.1136/gut.45.2.229

Basara, 2001, Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients, Transplant Proc, 33, 2121, 10.1016/S0041-1345(01)01968-6

Doney, 1981, Treatment of graft-versus-host disease in human allogeneic marrow graft recipients, Am J Hematol, 11, 1, 10.1002/ajh.2830110102

Anasetti, 1992, Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody, Transplantation, 54, 844, 10.1097/00007890-199211000-00015

Lee, 2004, Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease, Blood, 104, 1559, 10.1182/blood-2004-03-0854

Deeg, 2001, Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL, Blood, 98, 2052, 10.1182/blood.V98.7.2052

Grothaus-Pinke, 2001, Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel, Transplantation, 72, 1456, 10.1097/00007890-200110270-00022

Bertz, 1999, Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD, Bone Marrow Transplant, 24, 1185, 10.1038/sj.bmt.1702055

McDonald, 1998, Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease, Gastroenterology, 115, 28, 10.1016/S0016-5085(98)70361-0

French, 2000, Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease, Schweiz Med Wochenschr, 130, 1656

Biedermann, 2002, Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease, Lancet, 359, 2078, 10.1016/S0140-6736(02)08907-9